On May 22, 2026, a delegation from China Orient Asset Management Co., Ltd. paid a visit to Shenzhen-Hong Kong Cell Valley (Shenzhen) Medical Technology Co., Ltd. The two sides held in-depth exchanges covering cell and gene therapy industrial development, capital empowerment by central state-owned enterprises, innovative platform construction and prospective cooperation models.

Attendees from China Orient Asset Management included Sui Zhaohui, General Manager of Group Business Review Department; Liu Zhao, General Manager of Guangdong Branch; Wang Kun, General Manager of the Second Business Management Department; Dai Weihang from the Third Business Management Department; Xu Jianguo, Head of the Sixth Business Department; and Duan Ying, Assistant General Manager of Shenzhen Branch. Shi Yuanyuan, Founder and Chairman of Shenzhen Cell Valley Group, Wang Shaoqing, Chief Financial Officer, Wei Zheng, Chief Administrative Officer, Project Manager Wu Hua, Han Shu, Director of General Affairs Office of the subsidiary, and Fang Yixun, Marketing Director, received the guests.

During the visit, the delegation toured the facility and learned about the group’s development history, core technological platforms, industrial layout and clinical translation service system. As a one-stop CRO/CDMO and clinical translation service provider specializing in cell and gene therapy, Shenzhen Cell Valley boasts comprehensive capabilities spanning cell preparation, vector process development, quality inspection, clinical research support and industrial translation, striving to translate cutting-edge biomedical research into clinical practice.

At the symposium, both parties thoroughly discussed industry trends, regional platform development, capital support for biomedical innovators and joint clinical translation projects. Participants noted that improved regulatory policies have driven the industry into a critical phase of standardized, platform-based and large-scale expansion. Synergy between central enterprise capital, professional platforms and clinical resources can accelerate technological innovation and project implementation.

Chairman Shi Yuanyuan stated that the group will leverage its strengths in fundamental technology, GMP manufacturing, clinical translation and cross-regional platform development. It will pursue diverse cooperation with central enterprise capital, industrial investors and regional institutions to advance clinical research and biomedical innovation commercialization.

The visit deepened mutual understanding and laid a solid foundation for future collaboration in resource integration, project partnership, capital investment and joint platform building. Both parties agreed to maintain close communication, seek practical cooperation opportunities and jointly advance high-quality development and industrial application of cell and gene therapy technologies.